Adjunctive glucocorticoid therapy in patients with septic shock.
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether hydrocortisone reduces mortality among patients with septic shock is unclear. METHODS: We randomly assigned patients with septic shock who were undergoing mechanical ventilation to receive hydrocortisone (at a dose of 200 mg per day) or placebo for 7 days or until death or discharge from the intensive care unit (ICU), whichever came first. The primary outcome was death from any cause at 90 days. RESULTS: From March 2013 through April 2017, a total of 3800 patients underwent randomization. Status with respect to the primary outcome was ascertained in 3658 patients (1832 of whom had been assigned to the hydrocortisone group and 1826 to the placebo group). At 90 days, 511 patients (27.9%) in the hydrocortisone group and 526 (28.8%) in the placebo group had died (odds ratio, 0.95; 95% confidence interval [CI], 0.82 to 1.10; P=0.50). The effect of the trial regimen was similar in six prespecified subgroups. Patients who had been assigned to receive hydrocortisone had faster resolution of shock than those assigned to the placebo group (median duration, 3 days [interquartile range, 2 to 5] vs. 4 days [interquartile range, 2 to 9]; hazard ratio, 1.32; 95% CI, 1.23 to 1.41; P<0.001). Patients in the hydrocortisone group had a shorter duration of the initial episode of mechanical ventilation than those in the placebo group (median, 6 days [interquartile range, 3 to 18] vs. 7 days [interquartile range, 3 to 24]; hazard ratio, 1.13; 95% CI, 1.05 to 1.22; P<0.001), but taking into account episodes of recurrence of ventilation, there were no significant differences in the number of days alive and free from mechanical ventilation. Fewer patients in the hydrocortisone group than in the placebo group received a blood transfusion (37.0% vs. 41.7%; odds ratio, 0.82; 95% CI, 0.72 to 0.94; P=0.004). There were no significant between-group differences with respect to mortality at 28 days, the rate of recurrence of shock, the number of days alive and out of the ICU, the number of days alive and out of the hospital, the recurrence of mechanical ventilation, the rate of renal-replacement therapy, and the incidence of new-onset bacteremia or fungemia. CONCLUSIONS: Among patients with septic shock undergoing mechanical ventilation, a continuous infusion of hydrocortisone did not result in lower 90-day mortality than placebo. (Funded by the National Health and Medical Research Council of Australia and others; ADRENAL ClinicalTrials.gov number, NCT01448109 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“The optimal dose, timing of initiation, and duration of corticosteroids remain uncertain; recent RCTs used 200 mg per day of IV hydrocortisone in divided doses [354, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“The three trials [354, 478, 479] also used different inclusion criteria: in ADRENAL [479] eligible patients were those on any dose of vasopressor or inotrope for ≥ 4 h to maintain a MAP > 60 mmHg, and present at the time of randomisation.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationA Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationFleischmann, C., Scherag, A., Adhikari, N. K. J., Hartog, C. S., Tsaganos, T., Schlattmann, P., Angus, D. C., & Reinhart, K. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0781oc · Cited by 3,548
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated Inflammation
Chrousos, G. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322008 · Cited by 2,579
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014.
Rhee, C., Dantes, R., Epstein, L., Murphy, D. J., Seymour, C. W., Iwashyna, T. J., Kadri, S. S., Angus, D. C., Danner, R. L., Fiore, A. E., et al. (2017) · JAMA · doi:10.1001/jama.2017.13836 · Cited by 1,884
Cited by
Items 901–1,000 of 1,000
Corticosteroids in septic shock: a double-edged sword
Wang, J. Y., & Kollef, M. H. (2025) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001297 · Cited by 1
Danos, A., Lear, A., Roach, E. M., & Quinn, N. J. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251355619
“7,8 The APROCCHSS trial, utilizing hydrocortisone 50 mg IV every 6 hours plus fludrocortisone, found a benefit in mortality as well as vasopressor-free days compared to placebo.”
InfluentialEvaluation of Stress Dose Hydrocortisone Tapers in Septic Shock
Gilchrist, H. E., Roginski, M. A., & Esteves, A. M. (2025) · Hospital Pharmacy · doi:10.1177/00185787251355438
“4-6,12 The SSCG recommendations have”
Emami, E., Molaei, E., Ghazi, S. F., Sohrabi, M., & Khalili, H. (2025) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-025-00571-0
Sasidharan, S., Grewal, R., & Dilesh, P. K. (2025) · MRIMS Journal of Health Sciences · doi:10.4103/mjhs.mjhs_27_25
The power of the Pitt bacteremia score in bloodstream infections in older adults
Özalp, O., Muderrisoğlu, E., Tune, F., Yildiz, F. B. P., Özdemir, M. Ş., & Gündüz, A. (2025) · The Annals of Clinical and Analytical Medicine · doi:10.4328/acam.22781
Billig, S., Dermer, J., Kjærsgaard, L., Hamilton, J., & Yeung, J. (2025) · Resuscitation Plus · doi:10.1016/j.resplu.2025.101078
“6 Until now their role in post CA care remains unclear.”
Jeon, C. H., Sung, K., & Cho, J. (2025) · Surgical Infections · doi:10.1177/10962964251376959
Hydrocortisone–Fludrocortisone Combination in Septic Shock: Annane et al.
Chacko, J., Chalfin, D. B., Seppelt, I., Pawar, S., & Brar, G. (2025) · Springer eBooks · doi:10.1007/978-981-95-0673-6_29
Araneda, R. M., Moreno, V. M., Bustillos, A. C., & Peralta, F. V. (2025) · Revista Chilena de Anestesia · doi:10.25237/revchilanestv54n5-02
A tribute to Rinaldo Bellomo: Why randomised behaviour is better than random behaviour
Myburgh, J., & Venkatesh, B. (2025) · Critical Care and Resuscitation · doi:10.1016/j.ccrj.2025.100123
“…algo-rithm did not improve survival in patients with severe sepsis and the Adjunctive Glucocorticoid Therapy In Septic Shock Trial (AD-RENAL), 13 which addressed a clinical dilemma about the optimal dosing, efficacy, and safety of hydrocortisone for the treatment and reversal of septic shock…”
Self-citationUnravelling the paradox of vitamin C research in sepsis
Fujii, T., May, C. N., & Lankadeva, Y. R. (2025) · Critical Care and Resuscitation · doi:10.1016/j.ccrj.2025.100134
“6 The trial results were published in 2018 and were also accompanied by the updated meta-analysis.”
Honouring Rinaldo Bellomo’s tour de force in sepsis research
Peake, S., Delaney, A. P., & Venkatesh, B. (2025) · Critical Care and Resuscitation · doi:10.1016/j.ccrj.2025.100139
Self-citationRamanan, M., Kumar, A., Billot, L., Myburgh, J., & Venkatesh, B. (2025) · Critical Care and Resuscitation · doi:10.1016/j.ccrj.2025.100119 · Cited by 1
“7 In this context, alternatives to a priori consent, such as consent-to-continue (obtained after patient enrolment) and opt-out consent, 8 — 10 have been developed to give patients opportunities to participate in and benefit from RCTs, but also have opportunities to participate in informed consent…”
Self-citationSepsis y shock séptico en adultos
de Roquetaillade, C., Bousta, A., Muchardt, J., & Chousterman, B. G. (2025) · EMC - Anestesia-Reanimación · doi:10.1016/s1280-4703(25)51018-6
Sepsi e shock settico dell'adulto
de Roquetaillade, C., Bousta, A., Muchardt, J., & Chousterman, B. G. (2025) · EMC - Anestesia-Rianimazione · doi:10.1016/s1283-0771(25)51071-x
[Translated article] Sepsis and septic shock
Bastida, C., Lugea, A. E., Fernández-Polo, A., Moreno, F. B., Cerezuela, M. M., Chiva, E. D., García, T. B., García, M. Á. A., González, I., Albanell‐Fernández, M., et al. (2025) · Farmacia Hospitalaria · doi:10.1016/j.farma.2025.10.005 · Cited by 2
杨, 丽. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.131110
When and How Much? Steroids in Sepsis
CROSLEY, E. L., Yang, P., & Esper, A. M. (2025) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.10.004
Adrenal Insufficiency: Diagnostic Approaches, Treatments, and Outcomes Volume II
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-7003-6
Opdam, H. I., & Harvey, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11611-7.00115-8
Inotropes and vasopressors (vasoactive drugs)
Deane, A. M., Khanna, A. K., & Myburgh, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11611-7.00026-8
Self-citationAdrenocortical insufficiency in critical illness
Cohen, J., & Venkatesh, B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11611-7.00071-2
Self-citationMaiden, M. J., See, E. J., & Peake, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11611-7.00023-2
Corticosteroid Therapy in Cardiac Arrest: Evidence, Guidelines, and Future Directions
Abrahams, R. A., Singh, N. K., Fatehi, M. K., Weckerly, M. L., Mirzai, D. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001103
Additional file 6 of The story of critical care in Asia: a narrative review
Phua, J., 임채만, Faruq, M. O., Nafees, K. M. K., Du, B., Gomersall, C. D., Ling, L., Divatia, J., Hashemian, S. M., Egi, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16767664
Self-citationAdditional file 3 of Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
Jonmarker, S., Hollenberg, J., Dahlberg, M. J. A., Stackelberg, O., Litorell, J., Everhov, A. H., Järnbert‐Pettersson, H., Söderberg, M., Grip, J., Schandl, A. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13279836
Additional file 4 of Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
Jonmarker, S., Hollenberg, J., Dahlberg, M. J. A., Stackelberg, O., Litorell, J., Everhov, A. H., Järnbert‐Pettersson, H., Söderberg, M., Grip, J., Schandl, A. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13279839
Bauer, M., Gerlach, H., Vogelmann, T., Preissing, F., Stiefel, J., & Adam, D. (2020) · Figshare · doi:10.6084/m9.figshare.12332348
Obling, L. E. R., Beske, R. P., Meyer, M. A. S., Grand, J., Wiberg, S. C., Mohr, T., Damm-Hejmdal, A., Forman, J. L., Frikke-Schmidt, R., Folke, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25045543
Additional file 1 of Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
Jonmarker, S., Hollenberg, J., Dahlberg, M. J. A., Stackelberg, O., Litorell, J., Everhov, A. H., Järnbert‐Pettersson, H., Söderberg, M., Grip, J., Schandl, A. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13279830
Additional file 1 of Adaptive designs in critical care trials: a simulation study
Li, W., Cornelius, V. R., Finfer, S., Venkatesh, B., & Billot, L. (2024) · Figshare · doi:10.6084/m9.figshare.26628556
Self-citationMoskowitz, A., Andersen, L. W., Holmberg, M. J. J., Grossestreuer, A. V., Berg, K. M., & Granfeldt, A. (2020) · Figshare · doi:10.6084/m9.figshare.12629647
Bauer, M., Gerlach, H., Vogelmann, T., Preissing, F., Stiefel, J., & Adam, D. (2020) · Figshare · doi:10.6084/m9.figshare.12332354
Additional file 2 of Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
Jonmarker, S., Hollenberg, J., Dahlberg, M. J. A., Stackelberg, O., Litorell, J., Everhov, A. H., Järnbert‐Pettersson, H., Söderberg, M., Grip, J., Schandl, A. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13279833
Bauer, M., Gerlach, H., Vogelmann, T., Preissing, F., Stiefel, J., & Adam, D. (2020) · Figshare · doi:10.6084/m9.figshare.12332342
Additional file 1 of The story of critical care in Asia: a narrative review
Phua, J., 임채만, Faruq, M. O., Nafees, K. M. K., Du, B., Gomersall, C. D., Ling, L., Divatia, J., Hashemian, S. M., Egi, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16767649
Self-citationAdditional file 4 of The story of critical care in Asia: a narrative review
Phua, J., 임채만, Faruq, M. O., Nafees, K. M. K., Du, B., Gomersall, C. D., Ling, L., Divatia, J., Hashemian, S. M., Egi, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16767658
Self-citationKuo, K.-C., Chen, C.-H., Wang, C.-J., Wu, J.-C., Chung, H.-P., Chen, Y.-T., Tang, Y.-H., Chang, W.-K., Lin, C.-Y., & Wu, C.-L. (2022) · Figshare · doi:10.6084/m9.figshare.21229169
Additional file 3 of The story of critical care in Asia: a narrative review
Phua, J., 임채만, Faruq, M. O., Nafees, K. M. K., Du, B., Gomersall, C. D., Ling, L., Divatia, J., Hashemian, S. M., Egi, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16767655
Self-citationBauer, M., Gerlach, H., Vogelmann, T., Preissing, F., Stiefel, J., & Adam, D. (2020) · Figshare · doi:10.6084/m9.figshare.12332336
Jung, S.-Y., Lee, M.-T., Baek, M. S., & Kim, W.-Y. (2022) · Figshare · doi:10.6084/m9.figshare.17870328
Additional file 1 of Towards personalized medicine: a scoping review of immunotherapy in sepsis
Slim, M. A., van Mourik, N., Bakkerus, L., Fuller, K., Acharya, L. S., Giannidis, T., Dionne, J. C., Oczkowski, S. J. W., Netea, M. G., Pickkers, P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26726717
Additional file 5 of The story of critical care in Asia: a narrative review
Phua, J., 임채만, Faruq, M. O., Nafees, K. M. K., Du, B., Gomersall, C. D., Ling, L., Divatia, J., Hashemian, S. M., Egi, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16767661
Self-citationJung, S.-Y., Lee, M.-T., Baek, M. S., & Kim, W.-Y. (2022) · Figshare · doi:10.6084/m9.figshare.17870331
Bagate, F., Bedet, A., Tomberli, F., Boissier, F., Razazi, K., de Prost, N., Carteaux, G., & Dessap, A. M. (2021) · Figshare · doi:10.6084/m9.figshare.14489866
Additional file 5 of Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
Jonmarker, S., Hollenberg, J., Dahlberg, M. J. A., Stackelberg, O., Litorell, J., Everhov, A. H., Järnbert‐Pettersson, H., Söderberg, M., Grip, J., Schandl, A. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13279842
Garcia, J. B., Xian, J. Z., Pedroza, C., Salahuddin, M., Mak, G., Keene, A., Cherian, S., Young, A., Vijhani, P., & Doshi, P. (2020) · Figshare · doi:10.6084/m9.figshare.12781413
Additional file 2 of The story of critical care in Asia: a narrative review
Phua, J., Lim, C.-M., Faruq, M. O., Nafees, K. M. K., Du, B., Gomersall, C. D., Ling, L., Divatia, J., Hashemian, S. M., Egi, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16767652
Self-citationJung, S.-Y., Lee, M.-T., Baek, M. S., & Kim, W.-Y. (2022) · Figshare · doi:10.6084/m9.figshare.17870334
Liang, B., Su, J., Shao, H., Chen, H., & Xie, B. (2024) · Figshare · doi:10.6084/m9.figshare.26574941
Obling, L. E. R., Beske, R. P., Meyer, M. A. S., Grand, J., Wiberg, S. C., Mohr, T., Damm-Hejmdal, A., Forman, J. L., Frikke‐Schmidt, R., Folke, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25045628
Bauer, M., Gerlach, H., Vogelmann, T., Preissing, F., Stiefel, J., & Adam, D. (2020) · Figshare · doi:10.6084/m9.figshare.12332360
Cai, T., Chen, S., Wu, C., Lou, C., Wang, W., Lin, C., Jiang, H., & Xu, X. (2024) · Figshare · doi:10.6084/m9.figshare.26641804
Adjunctive Therapies in Sepsis: Corticosteroids, IVIG, Blood Purification, and More
Ekici, H., & Türe, Z. (2025) · doi:10.59537/saupress.2500
Precision Medicine in Sepsis: From Biomarkers to Bedside
MEŞE, E. A., YÜCE, Z. T., Eren, E. E., Tufan, Z. K., Eser, F., Oktay, Z., Beder, D., Yaman, M., Altındiş, M., Baddal, B., et al. (2025) · doi:10.59537/saupress.2486
Buensalido, J. A. L., Malundo, A. F. G., Aherrera, J. A. M., Magno, J. D. A., Maramara, M. K. P., Punzalan, F. E. R., Tolosa, M. T. S., Briones, G., Hernandez, A. M. R., Pantaleon, A. F., et al. (2022) · Philippine Journal of Internal Medicine · doi:10.65564/pjim.10a45be121
Sepsis in Cirrhosis: Challenges, Timely Diagnosis, and Optimal Antibiotic Strategies
Singh, S. P., Rudra, O. S., & Jothimani, D. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-2624-6_16
Huang, Z., Zhao, J., Yuan, Q., Yang, X., & Li, X. (2026) · Research Square · doi:10.21203/rs.3.rs-8297386/v1
Sun, A., Gao, X., Gao, Z., Zhang, Q., & He, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1755626
“However, the ADRENAL trial (35), which compared the efficacy of a daily intravenous infusion of 200 mg hydrocortisone versus placebo for 7 days in patients with septic shock, showed no significant difference in 90-day mortality between the two groups.”
Lactate Cut-offs for 28-day Mortality in Septic ShockPreprint
Wanka, S.-T., Hermann, A., Lenz, M., Hengstenberg, C., Schellongowski, P., Staudinger, T., & Zilberszac, R. (2026) · medRxiv · doi:10.64898/2026.02.08.26345840
Khan, A. S., Ahmad, F., Khan, A. A., Khan, Z., Ahmed, T., Wazir, A., Khan, H. U., Ali, A., Khan, H., Khan, A. Y., et al. (2026) · Medical Principles and Practice · doi:10.1159/000551004
“Two landmark clinical trials, ADRENAL and APROCCHSS, yielded conflicting data regarding the impact of hydrocortisone on 90-day survival rates; nevertheless, both studies confirmed that steroids accelerate the resolution of shock and decrease the time patients require mechanical ventilation [9, 10].”
Higher Serum Cortisol is Associated with Delayed Shock Resolution in Septic Shock Patients
Dumrongsukit, S., Charoensri, S., Mulalin, K., & Panitchote, A. (2026) · Journal of Intensive Care Medicine · doi:10.1177/08850666261423897
Lee, J. H., Sumer‐Bayraktar, Z., Rushworth, R. L., Chernykh, A., Nenke, M. A., Thaysen‐Andersen, M., Meyer, E. J., & Torpy, D. J. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag058
Islam, K. M. S., Alam, Z. N., Sharif, M., Hossain, F. S., Hossain, M. S., Sweety, K. A., Kabir, M. A., & Ahmed, M. U. (2026) · Journal of Medicine · doi:10.3329/jom.v27i1.88269
Corticosteroids for treating sepsis: A systematic review and network meta-analysis
Luo, X., Yang, J., Zhang, Z., Sun, H., Gao, M., & Wu, S. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108786
Ojeda, D., Ferrer, R., Garnacho‐Montero, J., Maseda-Garrido, E., & Ochagavía, A. (2026) · Medicina Intensiva · doi:10.1016/j.medin.2026.502448
A REVIEW OF CORTICOSTEROID THERAPY IN SEPTIC SHOCK: CONTROVERSIES AND CONSENSUS
Milkintaitė, G., Milašiūtė, G., & Pilvinis, V. (2026) · Sveikatos mokslai · doi:10.35988/sm-hs.2026.091
Zhang, T., Wan, Y., Wan, J., Han, Z., Min, S., & Chen, S. (2026) · BMC Anesthesiology · doi:10.1186/s12871-026-03613-5
“Although therapies have advanced, mortality remains ≈ 15–20% in sepsis and rises sharply to 40–50% in septic shock [3, 4], with a recent multicenter trial of mechanically ventilated septic shock patients reporting 90-day mortality of 28.4% [5].”
InfluentialMahajan, A., Beattie, N., Patel, N. P., Tran, A. H., Ho, V. P., & Dvorak, J. E. (2026) · Surgical Infections · doi:10.1177/10962964261437315
Régulation de la réponse immunitaire au cours du sepsis
Alby‐Laurent, F. (2018) · theses.fr (ABES) · doi:10.70675/780838fbzf396z4b3fz9c2dz8729a7dec685
Qui est l'assassin au cours du sepsis? : l'inflammation ou la prolifération bactérienne ?
de Tymowski, C. (2020) · theses.fr (ABES) · doi:10.70675/ed19121fza61fz403czb053z70b4c1f5a3a6
Impact de la corticothérapie dans les infections invasives à Neisseria meningitidis
Levy, M. (2018) · theses.fr (ABES) · doi:10.70675/4267c369z9f77z4ed0z958cze23c84578c13
Propriétés immunes de la cellule endothéliale au cours du sepsis
Pons, S. (2021) · theses.fr (ABES) · doi:10.70675/3999fc10z25d2z4513z87dazc18894ab82dd
Vermeersch, V. (2023) · theses.fr (ABES) · doi:10.70675/208ba22bz2ec2z47d3z9889z4157016e475d
Implication de l'axe C5a-C5aR1 dans l'orage inflammatoire des formes sévères de COVID-19 de l'adulte
Carvelli, J. (2023) · theses.fr (ABES) · doi:10.70675/be12640bzc919z4322zb146z5a584bd7ec67
Hibbert, E., Leggett, N. E., Kim, D., Silva, S. D., Messiha, R., Abbenbroek, B., Campbell, L. T., Deane, A., Dye, J., Eastwood, G. M., et al. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag102
Self-citationLi, Y., Ding, H., & Li, X. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13418-z · Cited by 1
“Similarly, APROCCHSS and ADRENAL reported discordant findings [8, 23]; 90% of APROCCHSS participants were mechanically ventilated and older (mean age 66 ± 14 years), whereas only 30% of ADRENAL patients received ventilation.”
Adrenal Emergencies in Critically Ill Cancer Patients
Popovich, J. J., & Enfield, K. B. (2026) · Springer eBooks · doi:10.1007/978-3-319-74698-2_81-2
Andaluz‐Ojeda, D., Ferrer, R., Garnacho‐Montero, J., Maseda-Garrido, E., & Ochagavía, A. (2026) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2026.502448
Refractory Shock in the Post–Cardiac Arrest Patient
Walker, A. C., & Johnson, N. J. (2026) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2026.04.003
Early Corticosteroid use and Clinical Outcomes in Patients with Mixed and Cardiogenic Shock
Gastanadui, M. G., Murphy, H. R., Shahu, A., Safiriyu, I., Heck, C., Hysolli, M., Callegari, S., Garimella, S., Ali, T. M., Jentzer, J. C., et al. (2026) · Journal of Intensive Care Medicine · doi:10.1177/08850666261437767
“11,12,26 If patients with cardiac involvement as part of their shock syndrome are less likely to bene fi t from steroids, one potential mechanism for the higher mortality could be the known adverse effects of steroids, including metabolic derangements, hyperglycemia, neuromuscular weakness, and…”
Identifying a Refractory Shock Phenotype in Pediatric Sepsis Using a Vasoactive-Adjusted Shock Index
Lee, C. M., Atreya, M. R., Bennett, T. D., Farris, R. W. D., Faustino, E. V. S., Geva, A., Rogerson, C. M., Shah, S., Weiss, S. L., & Sanchez-Pinto, L. N. (2026) · Shock · doi:10.1097/shk.0000000000002886
Munroe, E. S., Peltan, I. D., & Prescott, H. C. (2026) · Critical Care Clinics · doi:10.1016/j.ccc.2026.05.002
Mineralocorticoid magic? Evaluating fludrocortisone in septic shock
Tran, N., Ragoonanan, D., Posgai, L., Noble, M., & Cummings, J. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70638
“28,29 This coupled with the addition of fludrocorti-sone may have impacted the discordance in mortality findings between these two trials.”
Heming, N., Baron, Ė., Müller, G., Badie, J., Préau, S., Siami, S., Pouplet, C., Berger, A., Damoisel, C., Argaud, L., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-119187
Mugada, V. K., Saragadam, G. R. P., Rajana, A., & Arikitamula, R. (2026) · Prague Medical Report · doi:10.14712/23362936.2026.12
Eastwood, B., Terrington, I., Young, R. K., Cox, O., Webb, E., Mckenzie, C., Saeed, K. B. A., Morris, A. C., Grocott, M. P. W., & Dushianthan, A. (2026) · European Respiratory Review · doi:10.1183/16000617.0259-2025
“This is echoed in the published interim analysis after 950 patients (p=0.08) [109].”
InfluentialFarhati, V., Hunter, J., Sattwika, P. D., & Rozi, M. F. (2026) · Bali Journal of Anesthesiology · doi:10.4103/bjoa.bjoa_298_25
Hydrocortisone Use for Septic Shock in Patients With CKD
Dhamelia, P. M., Abeyagunawardene, H., Kore, R. A., Raghavan, D., Arthur, J. M., Vyas, K. S., Khandekar, N., & Jain, N. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106686
Use of corticosteroids in sepsis and infectious diseases: a narrative review
Kim, J. H. (2026) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2025.283
Pérez, I., Paredes, M. C., Barajas, O. L. T., & Sánchez, A. (2026) · Medicina Crítica · doi:10.35366/123477
Lac, J., Han, S., Ahmad, M., Starey, H., Ganguly, S., Tett, M., Adeyemi, O., Bray, J. J. H., Ahmad, M. T., & Providencia, R. A. (2026) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2025-003934
Carpenter, S. L., & Coopersmith, C. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-22660-0_26
The Endocrine Axis and Critical Illness
Kim, S. S., & Saillant, N. N. (2026) · Springer eBooks · doi:10.1007/978-3-032-22660-0_33
Yamaya, Y., Kuwana, T., Kinoshita, K., Takahashi, K., Nakabayashi, H., & Imai, T. (2026) · Medical Sciences · doi:10.3390/medsci14030394
“When high-dose vasopressor therapy was required, low-dose corticosteroids (hydrocortisone 200 mg/day) were generally administered [13].”
An International Survey of Corticosteroid Use in Septic Shock
Ho, J. C., Zamir, N., Pereira, T. V., Rochwerg, B. N., Bosch, N. A., Mazer, C. D., Kaufman, D. A., Yarnell, C. J., Law, A. C., Jivraj, N. K., et al. (2026) · CHEST Critical Care · doi:10.1016/j.chstcc.2026.100297
Metadata
- Authors
- Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., Billot, L., Correa, M., Glass, P., Harward, M., Joyce, C., Li, Q., McArthur, C., Perner, A., Rhodes, A., Thompson, K., Webb, S., & Myburgh, J.
- Affiliations
- The University of Sydney (AU)
- From the George Institute for Global Health, University of New South Wales (B.V., S.F., D.R., L.B., M.C., P.G., M.H., Q.L., K.T., J.M.), St. George Clinical School, St. George Hospital (J.M.), Sydney Medical School, University of Sydney (B.V., S.F., J.M.), and Royal North Shore Hospital (S.F.), Sydney, the Princess Alexandra Hospital (B.V., C.J.) and Royal Brisbane and Women’s Hospital (J.C.), University of Queensland, and the Wesley Hospital (B.V., J.C.), Brisbane, Austin Hospital (R.B.), the...
- University of Copenhagen (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 797-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2784412824
- Cited by
- 1,037
- References
- 40
- Citations by year
- 2026: 111 · 2025: 122 · 2024: 90 · 2023: 106 · 2022: 110 · 2021: 121 · 2020: 149 · 2019: 135 · 2018: 91
- FWCI
- 96.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Research Repository (Kingston University London) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- National Health and Medical Research Council (1004108, 1124926)
- Health Research Council of New Zealand (12/206)
- National Institute of Health Research, United Kingdom
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- septic shock, cortisol, mortality, mechanical ventilation, shock resolution, blood transfusion, intensive care unit, sepsis treatment, subgroup analysis, mechanical ventilation duration, vasopressor requirement, glycemic control
- MeSH terms
- Aged, Anti-Inflammatory Agents, Double-Blind Method, Female, Humans, Hydrocortisone, Infusions, Intravenous, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Rate, Fungemia, Bacteremia, Treatment Outcome, Chemotherapy, Adjuvant, Renal Replacement Therapy, APACHE
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.